16 Mar 2017
N+1 Singer - Oxford BioMedica - Full year results; anticipate CTL019 launch later this year
Oxford BioMedica’s full year results highlight a step up in bioprocessing and commercial development income following the manufacturing capacity expansion undertaken in 2015 and 2016. However, in the near term the financial outlook continues to look highly dependent on Novartis, which was responsible for the majority of the income increase as Oxford BioMedica supplied the lentiviral vector for CTL019 clinical trials. The group is confident of supplying the vector following regulatory approval o ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Oxford BioMedica - Full year results; anticipate CTL019 launch later this year
Oxford BioMedica plc (OXB:LON) | 197 0 0.0% | Mkt Cap: 196.9m
- Published:
16 Mar 2017 -
Author:
Sheena Berry -
Pages:
3
Oxford BioMedica’s full year results highlight a step up in bioprocessing and commercial development income following the manufacturing capacity expansion undertaken in 2015 and 2016. However, in the near term the financial outlook continues to look highly dependent on Novartis, which was responsible for the majority of the income increase as Oxford BioMedica supplied the lentiviral vector for CTL019 clinical trials. The group is confident of supplying the vector following regulatory approval o ....